Results 31 to 40 of about 340,090 (253)

Fusion assays for screening of fusion inhibitors targeting SARS-CoV-2 entry and syncytia formation

Frontiers in Pharmacology, 2022
Virus fusion process is evolutionarily conserved and provides a promising pan-viral target. Cell-cell fusion leads to syncytial formation and has implications in pathogenesis, virus spread and immune evasion.
Shiu-Wan Chan
doaj   +1 more source

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4

Viruses, 2019
The Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and caused continual outbreaks worldwide with high mortality. However, no effective anti-MERS-CoV drug is currently available.
Shuai Xia, Qiaoshuai Lan, Jing Pu, Cong Wang, Zezhong Liu, Wei Xu, Qian Wang, Huan Liu, Shibo Jiang, Lu Lu   +9 more
doaj   +1 more source

The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis

Вопросы вирусологии, 2020
This review article considers the possibilities of combined antiviral therapy in the treatment of patients with COVID-19, based on the analysis of the mechanism of action of known antiviral drugs in the framework of the medical hypothesis.
O. V. Gaisenok
doaj   +1 more source

Natural products as a source of Coronavirus entry inhibitors

Frontiers in Cellular and Infection Microbiology
The COVID-19 pandemic has had a significant and lasting impact on the world. Four years on, despite the existence of effective vaccines, the continuous emergence of new SARS-CoV-2 variants remains a challenge for long-term immunity.
Dávid Szabó, Dávid Szabó, Andrew Crowe, Andrew Crowe, Cyril Mamotte, Cyril Mamotte, Padraig Strappe, Padraig Strappe   +7 more
doaj   +1 more source

A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life

Molecules, 2019
Enfuvirtide (T20) is the first U.S. FDA-approved HIV fusion inhibitor-based anti-HIV drug. Its clinical application is limited because of its low potency and short half-life.
Shan Su, Giselle Rasquinha, Lanying Du, Qian Wang, Wei Xu, Weihua Li, Lu Lu, Shibo Jiang   +7 more
doaj   +1 more source

Lipogastrins as potent inhibitors of viral fusion

Biochimica et Biophysica Acta (BBA) - Biomembranes, 1997
The rate and extent of membrane fusion is markedly sensitive to membrane interfacial properties. Lipopeptides with hydrophilic peptide moieties will insert into membranes, leaving the peptide portion at the membrane-water interface. In this work, we have used a lipopeptide composed of the peptide [Nle15]-gastrin-(2-17)-amide covalently linked to 1,2 ...
Epand, Raquel F, Moroder, Luis, Lutz, Juergen, Flanagan, Thomas D, Nir, Shlomo, Epand, Richard M   +5 more
openaire   +2 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Development of potent pan‐coronavirus fusion inhibitors with a new design strategy

MedComm
Development of potent and broad‐spectrum drugs against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) remains one of the top priorities, especially in the cases of the emergence of mutant viruses and inability of current vaccines to prevent
Yuanmei Zhu, Zhongcai Gao, Xiaoli Feng, Lin Cheng, Nian Liu, Chao Liu, Shaowei Han, Qiaojiang Yang, Qingcui Zou, Huihui Chong, Zheng Zhang, Minghua Li, Gengshen Song, Yuxian He   +13 more
doaj   +1 more source

Addition of a short HIV-1 fusion-inhibitory peptide to PRO 140 antibody dramatically increases its antiviral breadth and potency

Journal of Virology
PRO 140, a humanized anti-HIV monoclonal antibody targeting the cell coreceptor CCR5, is currently under clinical trials, but it only affects CCR5-tropic viruses. In this study, we have engineered two tandem fusion proteins (2P23-PRO140SC and 2P23-PRO140-
Hongxia Yan, Yue Gao, Yuanmei Zhu, Huihui Chong, Yani Gong, Yue Chen, Li Li, Bin Su, Yuxian He   +8 more
doaj   +1 more source

The Curious Case of Arenavirus Entry, and Its Inhibition

Viruses, 2012
Arenaviruses comprise a diverse family of enveloped negative-strand RNA viruses that are endemic to specific rodent hosts worldwide. Several arenaviruses cause severe hemorrhagic fevers in humans, including Junín and Machupo viruses in South America and ...
Joanne York, Jack H. Nunberg
doaj   +1 more source